Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Chief Tech & Strategy Officer | February 26, 2019 | February 28, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date February 26, 2019 · Filed February 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,500 |
Reported balance
After 2019-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-26 · Grant · Acquired 4,500 · Balance 4,500 F1: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.47 · Expires 2028-01-24 | Direct | 5,625 |
Reported balance
After 2019-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-27 · Grant · Acquired 5,625 · Balance 5,625 F2: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4. F3: On February 27, 2019, the Compensation Committee determined and certified that 63.9% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4. F4: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020.
F2: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4.
F3: On February 27, 2019, the Compensation Committee determined and certified that 63.9% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4.
F4: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2019 Filed Feb 28, 2019 21:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 5,625 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-19-001382 · ownership.xml · derivative · entry 2 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 5,625 shares Expires 2028-01-24 F2 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 24, 2018, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 3 and 4. F3 · date: On February 27, 2019, the Compensation Committee determined and certified that 63.9% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 2 and 4. F4 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 27, 2019, January 1, 2020, January 1, 2021, and January 1, 2022. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 4,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-001382 · ownership.xml · derivative · entry 1 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 26, 2020. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 14:15 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 685 | $38.10 | $26,098.50 |
DisclosureSEC source: 0001171843-19-000755 · ownership.xml · nonDerivative · entry 1 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,575 F1 · shares: Reflects an aggregate of 685 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to restricted shares that vested in full on February 4, 2019. Read SEC document |
| March 02, 2018 Filed Mar 2, 2018 21:07 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 7,788 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-18-001659 · formfour.xml · derivative · entry 1 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,788 Underlying: Common Stock · 7,788 shares Expires 2027-01-27 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, January 27, 2017, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On March 2, 2018, the Compensation Committee determined and certified that 55% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in three equal installments on the following dates: March 2, 2018, January 1, 2019, and January 1, 2020. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 13,400 | $0.00 Strike: $61.47 | $0.00 |
DisclosureSEC source: 0001171843-18-000687 · formfour.xml · derivative · entry 1 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,400 Underlying: Common Stock · 13,400 shares Expires 2028-01-24 F1 · derivative.exercise_date: The stock options vest in four equal annual installments beginning January 24, 2019. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $38.11 | $0.00 |
DisclosureSEC source: 0001171843-17-001205 · formfour.xml · derivative · entry 2 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2026-02-04 F1 · derivative.exercise_price: The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, February 4, 2016, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3. F2 · date: On February 24, 2017, the Compensation Committee determined and certified that 125% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3. F3 · derivative.exercise_date: The stock options vest in four equal installments on the following dates: February 24, 2017, January 1, 2018, January 1, 2019 and January 1, 2020. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 640 | $49.47 | $31,660.80 |
DisclosureSEC source: 0001171843-17-001205 · formfour.xml · nonDerivative · entry 1 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,260 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 21:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $50.13 | $0.00 |
DisclosureSEC source: 0001171843-17-000583 · formfour.xml · derivative · entry 1 Ahn Edward S. · CIK 0001623597 · Chief Tech & Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2027-01-27 F1 · derivative.exercise_date: The stock options vest in three equal annual installments beginning January 27, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.